Last reviewed · How we verify
autologous immune cell therapy — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
autologous immune cell therapy (autologous immune cell therapy) — Shanghai AbelZeta Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| autologous immune cell therapy TARGET | autologous immune cell therapy | Shanghai AbelZeta Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- autologous immune cell therapy CI watch — RSS
- autologous immune cell therapy CI watch — Atom
- autologous immune cell therapy CI watch — JSON
- autologous immune cell therapy alone — RSS
Cite this brief
Drug Landscape (2026). autologous immune cell therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-immune-cell-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab